Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver

Aliya Qayyum, Gerard K. Lee, Benjamin M. Yeh, Jill N. Allen, Alan P. Venook, Fergus Coakley

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: This study aimed to determine the frequency of hepatic contour abnormalities and signs of portal hypertension at serial CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Materials and Methods: We retrospectively identified 91 women with breast cancer metastatic to the liver who received chemotherapy and underwent serial CT at our institution between 1998 and 2002. Two readers independently categorized hepatic contour abnormalities on the final CT examination as none, limited retraction, widespread retraction, or diffuse nodularity. Readers also recorded the development of hepatic atrophy or enlargement, ascites, portosystemic collateral veins, and splenomegaly. Interpretative discrepancies were resolved by consensus. Portal hypertension was defined as the presence of at least two of the following CT signs: simple ascites, portosystemic collateral veins, and splenomegaly. Results: After a median follow-up interval of 15 months (range, 1-46), hepatic contour abnormalities were seen in 68 of 91 patients (75%) and consisted of limited retraction (n=42), widespread retraction (n=10), or diffuse nodularity (n=16). Portal hypertension was found in 1 of 23 patients without contour abnormalities, in 1 of 42 patients with limited retraction, in none of 10 patients with widespread retraction, and in 6 of 16 patients with diffuse nodularity (P

Original languageEnglish (US)
Pages (from-to)6-10
Number of pages5
JournalClinical Imaging
Volume31
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Portal Hypertension
Breast Neoplasms
Drug Therapy
Liver
Splenomegaly
Ascites
Veins
Atrophy

Keywords

  • Breast neoplasms
  • CT
  • Liver neoplasms
  • Metastases
  • Therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. / Qayyum, Aliya; Lee, Gerard K.; Yeh, Benjamin M.; Allen, Jill N.; Venook, Alan P.; Coakley, Fergus.

In: Clinical Imaging, Vol. 31, No. 1, 01.2007, p. 6-10.

Research output: Contribution to journalArticle

Qayyum, Aliya ; Lee, Gerard K. ; Yeh, Benjamin M. ; Allen, Jill N. ; Venook, Alan P. ; Coakley, Fergus. / Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. In: Clinical Imaging. 2007 ; Vol. 31, No. 1. pp. 6-10.
@article{2693da906633436e936129b0de7d9ac4,
title = "Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver",
abstract = "Purpose: This study aimed to determine the frequency of hepatic contour abnormalities and signs of portal hypertension at serial CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Materials and Methods: We retrospectively identified 91 women with breast cancer metastatic to the liver who received chemotherapy and underwent serial CT at our institution between 1998 and 2002. Two readers independently categorized hepatic contour abnormalities on the final CT examination as none, limited retraction, widespread retraction, or diffuse nodularity. Readers also recorded the development of hepatic atrophy or enlargement, ascites, portosystemic collateral veins, and splenomegaly. Interpretative discrepancies were resolved by consensus. Portal hypertension was defined as the presence of at least two of the following CT signs: simple ascites, portosystemic collateral veins, and splenomegaly. Results: After a median follow-up interval of 15 months (range, 1-46), hepatic contour abnormalities were seen in 68 of 91 patients (75{\%}) and consisted of limited retraction (n=42), widespread retraction (n=10), or diffuse nodularity (n=16). Portal hypertension was found in 1 of 23 patients without contour abnormalities, in 1 of 42 patients with limited retraction, in none of 10 patients with widespread retraction, and in 6 of 16 patients with diffuse nodularity (P",
keywords = "Breast neoplasms, CT, Liver neoplasms, Metastases, Therapy",
author = "Aliya Qayyum and Lee, {Gerard K.} and Yeh, {Benjamin M.} and Allen, {Jill N.} and Venook, {Alan P.} and Fergus Coakley",
year = "2007",
month = "1",
doi = "10.1016/j.clinimag.2006.09.028",
language = "English (US)",
volume = "31",
pages = "6--10",
journal = "Clinical Imaging",
issn = "0899-7071",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver

AU - Qayyum, Aliya

AU - Lee, Gerard K.

AU - Yeh, Benjamin M.

AU - Allen, Jill N.

AU - Venook, Alan P.

AU - Coakley, Fergus

PY - 2007/1

Y1 - 2007/1

N2 - Purpose: This study aimed to determine the frequency of hepatic contour abnormalities and signs of portal hypertension at serial CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Materials and Methods: We retrospectively identified 91 women with breast cancer metastatic to the liver who received chemotherapy and underwent serial CT at our institution between 1998 and 2002. Two readers independently categorized hepatic contour abnormalities on the final CT examination as none, limited retraction, widespread retraction, or diffuse nodularity. Readers also recorded the development of hepatic atrophy or enlargement, ascites, portosystemic collateral veins, and splenomegaly. Interpretative discrepancies were resolved by consensus. Portal hypertension was defined as the presence of at least two of the following CT signs: simple ascites, portosystemic collateral veins, and splenomegaly. Results: After a median follow-up interval of 15 months (range, 1-46), hepatic contour abnormalities were seen in 68 of 91 patients (75%) and consisted of limited retraction (n=42), widespread retraction (n=10), or diffuse nodularity (n=16). Portal hypertension was found in 1 of 23 patients without contour abnormalities, in 1 of 42 patients with limited retraction, in none of 10 patients with widespread retraction, and in 6 of 16 patients with diffuse nodularity (P

AB - Purpose: This study aimed to determine the frequency of hepatic contour abnormalities and signs of portal hypertension at serial CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Materials and Methods: We retrospectively identified 91 women with breast cancer metastatic to the liver who received chemotherapy and underwent serial CT at our institution between 1998 and 2002. Two readers independently categorized hepatic contour abnormalities on the final CT examination as none, limited retraction, widespread retraction, or diffuse nodularity. Readers also recorded the development of hepatic atrophy or enlargement, ascites, portosystemic collateral veins, and splenomegaly. Interpretative discrepancies were resolved by consensus. Portal hypertension was defined as the presence of at least two of the following CT signs: simple ascites, portosystemic collateral veins, and splenomegaly. Results: After a median follow-up interval of 15 months (range, 1-46), hepatic contour abnormalities were seen in 68 of 91 patients (75%) and consisted of limited retraction (n=42), widespread retraction (n=10), or diffuse nodularity (n=16). Portal hypertension was found in 1 of 23 patients without contour abnormalities, in 1 of 42 patients with limited retraction, in none of 10 patients with widespread retraction, and in 6 of 16 patients with diffuse nodularity (P

KW - Breast neoplasms

KW - CT

KW - Liver neoplasms

KW - Metastases

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33845636232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845636232&partnerID=8YFLogxK

U2 - 10.1016/j.clinimag.2006.09.028

DO - 10.1016/j.clinimag.2006.09.028

M3 - Article

VL - 31

SP - 6

EP - 10

JO - Clinical Imaging

JF - Clinical Imaging

SN - 0899-7071

IS - 1

ER -